Aura Biosciences, Inc. (AURA) Stock Forecast
AURA analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $16.60 average of analyst targets
- Upside to target
- +172.1% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.31
- 52-week range
- $4.97 – $8.90
AURA analyst ratings
6 analystsNumber of analysts at each rating.
AURA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AURA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.37 | −$0.41 | −$0.32 | −$0.40 | +8.1% | 4 |
| Current fiscal year (2026) | −$1.67 | −$1.78 | −$1.50 | −$1.76 | +5.4% | 4 |
| Next fiscal year (2027) | −$1.52 | −$1.70 | −$1.15 | −$1.67 | +8.9% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AURA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $4.9M | $0 | $19.7M | 0.0% | 4 |
AURA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AURA revenue: reported and forecast
AURA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.37 | −$0.37 | −$0.37 | −$0.37 | −$0.37 | 0.0% | 1 up · 3 down |
| Current fiscal year (2026) | −$1.59 | −$1.59 | −$1.59 | −$1.59 | −$1.67 | +4.4% | 1 up · 3 down |
| Next fiscal year (2027) | −$1.67 | −$1.67 | −$1.67 | −$1.67 | −$1.52 | −9.0% | 3 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AURA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AURA beat in 8 of 12.
What analysts expect from AURA
6 analysts cover Aura Biosciences; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $16.60, 172.1% above the latest close of $6.10. Analysts expect earnings of −$1.67 per share for 2026, +5.4% from a year earlier. For 2027 the average estimate is −$1.52 per share on revenue of $4.9 million. Aura Biosciences beat the EPS estimate in 8 of the last 12 quarters.
Related: AURA income statement, AURA key metrics, AURA chart. See the AURA stock overview for the latest quote and news.
AURA forecast FAQ
What is Aura Biosciences's price target?
The average analyst price target for Aura Biosciences is $16.60, 172.1% above the latest close of $6.10.
Is Aura Biosciences a buy, hold or sell?
Of 6 analysts covering Aura Biosciences, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aura Biosciences's EPS forecast?
Analysts forecast −$1.67 per share for 2026 (range −$1.78 to −$1.50); for 2027 the estimate is −$1.52.
When does Aura Biosciences report earnings?
Aura Biosciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.31.
Does Aura Biosciences usually beat earnings estimates?
Aura Biosciences reported EPS at or above the analyst estimate in 8 of the last 12 quarters.